Shots:
- Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of Rs. 39/tablet
- Cipla receives the DCGI approval for Ciplenza (favipiravir, 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the first week of August priced at Rs 68/ tablet
- Moreover, Brinton gets DCGI approval drug favipiravir under the brand name Faviton (Rs 59/ tablet) for the treatment of COVID-19 patients. Faviton is a generic version of Avigan of Fujifilm Toyama, a subsidiary of Fujifilm Corporation
Cipla, Jenburkt, Brinton read full press release/ article | Ref: Cipla, Jenburkt, Brinton | Image: Pharmashots
